BridgeBio 製藥公司
US ˙ NasdaqGS ˙ US10806X1028

SecurityBBIO / BridgeBio Pharma, Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership270,928 shares
Latest Disclosed Value $ 11,698,671
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series reports 13.09% increase in ownership of BBIO / BridgeBio Pharma, Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 270,928 shares of BridgeBio Pharma, Inc. (US:BBIO) valued at $11,698,671 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 239,561 shares of BridgeBio Pharma, Inc.. This represents a change in shares of 13.09% during the quarter. The current value of the position is $18,317,442 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Bridgebio Pharma EC US10806X1028 270,928 31,367 13.09 11,699 41.26 0.2627
2025-05-28 2025-03-31 NP Bridgebio Pharma EC US10806X1028 239,561 2,543 1.07 8,282 27.34 0.1987
2025-02-25 2024-12-31 NP Bridgebio Pharma EC US10806X1028 237,018 -39,337 -14.23 6,504 -7.56 0.1420
2024-11-26 2024-09-30 NP Bridgebio Pharma EC US10806X1028 276,355 55,055 24.88 7,036 25.51 0.1331
2024-08-26 2024-06-30 NP Bridgebio Pharma EC US10806X1028 221,300 19,110 9.45 5,606 -10.33 0.1142
2024-05-28 2024-03-31 NP Bridgebio Pharma EC US10806X1028 202,190 -6,339 -3.04 6,252 -25.74 0.1305
2024-02-26 2023-12-31 NP Bridgebio Pharma EC US10806X1028 208,529 14,328 7.38 8,418 64.38 0.1797
2023-11-28 2023-09-30 NP Bridgebio Pharma EC US10806X1028 194,201 -4,083 -2.06 5,121 50.18 0.1336
2023-08-25 2023-06-30 NP Bridgebio Pharma EC US10806X1028 198,284 28,547 16.82 3,410 21.18 0.0809
2023-05-26 2023-03-31 NP Bridgebio Pharma EC US10806X1028 169,737 4,686 2.84 2,814 123.87 0.0749
2023-02-24 2022-12-31 NP Bridgebio Pharma EC US10806X1028 165,051 -1,759 -1.05 1,258 -24.19 0.0346
2022-11-25 2022-09-30 NP Bridgebio Pharma EC US10806X1028 166,810 2,630 1.60 1,658 11.28 0.0475
2022-08-25 2022-06-30 NP Bridgebio Pharma EC US10806X1028 164,180 0 0.00 1,491 -10.56 0.0412
2022-05-26 2022-03-31 NP Bridgebio Pharma EC US10806X1028 164,180 1,710 1.05 1,666 -38.50 0.0388
2022-02-25 2021-12-31 NP Bridgebio Pharma EC US10806X1028 162,470 -602 -0.37 2,710 -64.56 0.0588
2021-11-24 2021-09-30 NP Bridgebio Pharma EC US10806X1028 163,072 338 0.21 7,643 -22.95 0.1684
2021-08-26 2021-06-30 NP Bridgebio Pharma EC US10806X1028 162,734 19,916 13.95 9,920 12.77 0.2128
2021-05-27 2021-03-31 NP Bridgebio Pharma EC US10806X1028 142,818 27,959 24.34 8,798 7.71 0.1995
2021-02-25 2020-12-31 NP Bridgebio Pharma EC US10806X1028 114,859 -3,018 -2.56 8,168 84.69 0.2093
2020-11-25 2020-09-30 NP Bridgebio Pharma EC US10806X1028 117,877 -5,951 -4.81 4,423 9.51 0.1419
2020-08-27 2020-06-30 NP Bridgebio Pharma EC US10806X1028 123,828 -286 -0.23 4,038 12.20 0.1320
2020-06-01 2020-03-31 NP Bridgebio Pharma EC US10806X1028 124,114 89,164 255.12 3,599 194.04 0.1471
2020-02-27 2019-12-31 NP Bridgebio Pharma EC 10806X102 34,950 503 1.46 1,225 65.63 0.0368
2019-11-27 2019-09-30 NP Bridgebio Pharma EC US10806X1028 34,447 34,447 740 0.0244
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.